Literature DB >> 28577949

Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.

Masaya Yotsukura1, Hiroyuki Yasuda2, Takao Shigenobu1, Kaoru Kaseda1, Kyohei Masai1, Yuichiro Hayashi3, Tomoyuki Hishida1, Takashi Ohtsuka1, Katsuhiko Naoki4, Kenzo Soejima4, Tomoko Betsuyaku4, Hisao Asamura1.   

Abstract

OBJECTIVES: Over the past decade, the biological and clinical characteristics of lung cancer with epidermal growth factor receptor (EGFR) mutation have been well studied. However, most studies have focused on advanced inoperable cancer, and not on resected early-stage lung adenocarcinoma. We aimed to elucidate the differences in the clinicopathological characteristics and postoperative prognosis according to the EGFR mutation status in early-stage lung adenocarcinoma.
MATERIALS AND METHODS: We retrospectively collected clinical and pathological data from 369 patients with pathological stage I or II lung adenocarcinoma who underwent complete resection. Clinicopathological characteristics and postoperative prognosis were compared depending on the EGFR mutation status, using the Chi-squared test and the log-rank test, respectively. RESULTS AND
CONCLUSION: Of the 369 patients, 160 (43.3%) had EGFR mutation, of which 64 (40.0%) were exon 19 deletion (Del-19) and 90 (56.3%) were exon 21 point mutation L858R. Although there was no difference in overall survival (OS) between patients with and without EGFR mutation (p=0.086), tumors with EGFR mutation were associated with a lower consolidation to tumor ratio (CTR) (p <0.001) and a higher incidence of a lepidic growth pattern by pathological evaluation (p <0.001) compared to those without EGFR mutation. Among tumors with EGFR mutation, there was no difference in OS (p=0.140) between Del-19 and L858R. Tumors with L858R were associated with a lower CTR (p=0.046), and tended to have a higher incidence of a lepidic growth pattern by pathological evaluation (p=0.073) compared to those with Del-19. In conclusion, although EGFR mutation status was not a prognostic indicator after surgery in early-stage lung adenocarcinoma, L858R and Del-19 had different radiological and pathological features.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EGFR mutation; Lung cancer; Prognostic factor

Mesh:

Substances:

Year:  2017        PMID: 28577949     DOI: 10.1016/j.lungcan.2017.04.014

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  13 in total

1.  Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.

Authors:  R Li; Q Li; S Lin; W Li; L Yu; L Wang; X Dong; L Yu; S Li; W Liu; B Li
Journal:  Clin Transl Oncol       Date:  2018-07-18       Impact factor: 3.405

2.  Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma.

Authors:  Wang-Yu Zhu; Hai-Feng Li; Ke-Xin Fang; Bing-Jie Zhang; Shi-Quan Zhou; Yong-Kui Zhang; Han-Bo Le; Xiao-Fei Hu
Journal:  Dis Markers       Date:  2018-04-24       Impact factor: 3.434

3.  Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Shi-Ming Zhang; Qing-Ge Zhu; Xiao-Xiao Ding; Song Lin; Jing Zhao; Lei Guan; Ting Li; Bing He; Hu-Qin Zhang
Journal:  Cancer Manag Res       Date:  2018-09-10       Impact factor: 3.989

4.  Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study.

Authors:  Niraj Kumari; Shalini Singh; Dhanjit Haloi; Shravan Kumar Mishra; Narendra Krishnani; Alok Nath; Zafar Neyaz
Journal:  World J Oncol       Date:  2019-06-29

5.  Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer.

Authors:  Shuo Wang; Xiujuan Qu; Lili Cao; Xuejun Hu; Kezuo Hou; Yunpeng Liu; Xiaofang Che
Journal:  Cancer Manag Res       Date:  2020-05-28       Impact factor: 3.989

6.  The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion.

Authors:  Yun Du; Xiao Guo; Rui Wang; Yang Ma; Yan Zhang; Ying Liu; Lvli Dong; Juan Wu; Xiaokun Ji; Heng Wang
Journal:  J Cancer       Date:  2020-02-06       Impact factor: 4.207

7.  Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma.

Authors:  Lei Cai; Jiangfeng Wang; Junrong Yan; Jian Zeng; Liang Zhu; Jinxiao Liang; Chao Pan; Xiancong Huang; Ju Jin; Yang Xu; Fufeng Wang; Yang Shao; Qinqin Xu; Guojie Xia; Minyan Xing; Xiaoling Xu; Youhua Jiang
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

8.  Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery.

Authors:  Lu Yang; Chong Pang; Fei Xu; Guangjian Yang; Haiyan Xu; Changli Wang; Yan Wang
Journal:  Cancer Manag Res       Date:  2020-12-07       Impact factor: 3.989

9.  The multidisciplinary team plays an important role in the prediction of small solitary pulmonary nodules: a propensity-score-matching study.

Authors:  Chaoyuan Liu; Lishu Zhao; Fang Wu; Yeqian Feng; Rong Jiang; Chunhong Hu
Journal:  Ann Transl Med       Date:  2019-12

10.  Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.

Authors:  Tetsuya Isaka; Haruhiko Nakayama; Hiroyuki Ito; Tomoyuki Yokose; Kouzo Yamada; Munetaka Masuda
Journal:  BMC Cancer       Date:  2018-10-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.